Post-earnings recap
Reported
Mon, May 15, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Aurinia Pharmaceuticals reported a loss of $0.20 per share, with no revenue figures disclosed. The stock reacted negatively, dropping 5.73%, likely due to the lack of positive financial metrics and guidance. Investors may be concerned about the company's performance and future prospects given these results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.20 | N/A | — |
| Revenue | $— | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.